Biostage (NSDQ:BSTG) touted today the first patient use of its Cellspan esophageal implant.
The Holliston, Mass.-based company said that the regenerative implant was used in a 75-year old male patient, who has a life-threatening cancerous mass in his chest. Surgeons removed the portion of his esophagus affected by the cancer and Biostage’s implant was used to reconstruct the organ.